Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 211 - 220 of 317

Selected Filters:
7 July 2022

BioPIC Adaptable Product Introduction Framework

This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in…

Community/Advocacy, Demand Creation/Marketing, Financing & Costing, Research, Monitoring & Evaluation, Service Delivery, Supply Chain Management

External Link
7 July 2022

Knowledge, Attitudes and Practices of PrEP Providers Working with Adolescent Girls and Young Women

A review of completed, ongoing and planned studies exploring Knowledge, Attitudes and Practices of PrEP Providers Working with Adolescent Girls and Young Women

Research

Document
7 July 2022

Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis

The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.

Research

External Link
7 July 2022

HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring

This presentation outlines lessons from oral PrEP demonstration projects that could be applied to the rollout of the dapivirine vaginal ring as well as plans for ring introduction.

Research

Document
7 July 2022

Health Care Providers’ Attitudes toward and Experiences Delivering Oral PrEP to Adolescent Girls and Young Women in Kenya, South Africa, and Zimbabwe

This article describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya, South Africa, and Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

External Link
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Kenya technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Zimbabwe technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness

A vaginal ring containing dapivirine is effective for HIV prevention as pre-exposure prophylaxis (PrEP). The authors of this article evaluated the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Research, Service Delivery

External Link